Schaeffer's 43rd Anniversary Stock Picks in 2024

Analyst Update: Twitter Inc, Vertex Pharmaceuticals Incorporated, and Inovio Pharmaceuticals Inc

Analysts are weighing in on Twitter Inc (NYSE:TWTR), Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), and Inovio Pharmaceuticals Inc (NASDAQ:INO)

Oct 24, 2016 at 3:10 PM
facebook X logo linkedin

Analysts are weighing in on social media stock Twitter Inc (NYSE:TWTR), as well as biotechs Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) and Inovio Pharmaceuticals Inc (NASDAQ:INO). Here's a quick roundup of today's brokerage notes on TWTR, VRTX, and INO.

  • It's been a volatile day so far for TWTR, following a note from Morgan Stanley. The brokerage firm said it believes the social media company's third-quarter earnings -- due out on Thursday afternoon -- will show a decline in ad revenue, which will extend into the fourth quarter. Meanwhile, Axiom increased its third-quarter earnings outlook for TWTR, but maintained its "hold" recommendation, citing "rising competition for user time from Snapchat and Instagram, and pricing that is at a premium [to] other platforms."

    Although the stock dropped more than 3% earlier, it was last seen slightly higher at $18.15. Of course, Twitter Inc shares have been battered over the past 12 months, sliding 41%. Amid this fall, short sellers have been cashing in their winning bets. Since peaking in mid-May, short interest has declined 39.4%, and it would take less than one day to cover the remaining shorted shares, at the stock's average pace of trading.
  • VRTX has shed 1.8% today to trade at $79.32, after H.C. Wainwright downgraded the stock to "neutral" from "buy" and dropped its price target to $85, saying the drugmaker may have missed the boat on dominating the cystic fibrosis market. The brokerage firm added, "We do not view this company as able to sustain a valuation far in excess of its current $20 bln in the near term." Today's drop is more of the same for a stock that's now down 37% since the start of the year, and additional losses could spark more downgrades. For example, Vertex Pharmaceuticals Incorporated sports 11 "buy" or "strong buy" ratings, while not a single brokerage firm recommends selling the shares. Looking ahead, the company will report third-quarter earnings after tomorrow's close. 

  • INO is getting pummeled today, down 17% at $6.94 --- earning a spot on the short-sale restricted list -- after the Food and Drug Administration (FDA) put a clinical hold on the company's proposed late-stage trial for its cancer treatment, saying it needs more information to move forward. In response, Stifel dropped its price target on Inovio Pharmaceuticals Inc to $11 from $13, but maintained its "buy" opinion. The brokerage firm said, "Importantly, this clinical hold is not due to any dosing or safety concerns," and that the additional data requested by the FDA will be "straightforward to generate." Still, INO is on pace for its first close below its 320-day moving average since its late-March bull gap. This is just fine with short sellers, though, who control one-fifth of the stock's float. 
Don't miss the market's next move! Sign up now for Schaeffer's Midday Market Check

A.I.’s Dirty Little Secret: The Real Power Behind The AI. Boom ✨

Anyone who’s seen the The Matrix movies knows that A.I. needs power.  Lots and lots of power.

If you’ve seen the movie, you also know the grizzly results of the ensuing battle for that power.

Now, Wall Street’s battle for A.I. power won’t go to such extremes. Hopefully?

A.I. needs more power and that means more opportunities for stock traders in the know.

Download your free copy of “The A.I. Revolution: 4 Stocks to Buy Now”!